Page 11234..1020..»

Archive for the ‘Death by Stem Cells’ Category

Preventing misleading claim of COVID-19 cure – The Jakarta Post – Jakarta Post

Wednesday, June 17th, 2020

Researchers atAirlangga University (Unair) and the State Intelligence Agency (BIN) released on June 12what appeared to be an encouraging statement:the discovery of five combination drug therapies and two stem cell therapies for treating COVID-19. The acute respiratory disease caused by the SARS-CoV-2 virus has claimed at least 2,000 lives in Indonesia to date. The joint statementattributed to Unair andBIN also said that themedicines were ready for distributionin treating COVID-19 patients.

Read More...

FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA (pembrolizumab), Regardless of Tumor Type – The Baytown Sun

Wednesday, June 17th, 2020

KENILWORTH, N.J.--(BUSINESS WIRE)--Jun 17, 2020-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response

Read More...

OPINION: COVID-19 Reveals the Caregiving Mystique – Next Avenue

Wednesday, June 17th, 2020

Americas 66 million (pre-COVID-19) family caregivers people caring for loved ones with complex, chronic and ongoing care needs are thrust into their role with no training, no background and no support infrastructure. Preposterously, most feel like the only one on earth. Why

Read More...

The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor…

Wednesday, June 17th, 2020

Chen Q, Zeng X, Huang D, Qiu X. Identification of differentially expressed miRNAs in early-stage cervical cancer with lymph node metastasis across The Cancer Genome Atlas datasets. Cancer Manag Res

Read More...

Response to Covid has come at the cost of tackling the more fatal cancer – ThePrint

Wednesday, June 17th, 2020

Text Size:A- A+ It has been a while since I thought back to that week in 2012 when I received news that three close family members had been diagnosed with cancer two in my household. Newly published figures on how Covid-19 has delayed cancer referrals and treatments brought the memory back

Read More...

Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients – Business Wire

Wednesday, June 17th, 2020

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia was published online at medRxiv.org (www.medrxiv.org/content/10.1101/2020.06.08.20125369v1)

Read More...

Fear, Illness and Death in ICE Detention: How a Protest Grew on the Inside – The New York Times

Thursday, June 4th, 2020

I called Barahonas dorm immediately after I learned the news. There was one person who tested positive, Barahona said, right away. Its here.

Read More...

Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Krner…

Thursday, June 4th, 2020

The current coronavirus pandemic clearly illustrates how dangerous viral infections can become for us.

Read More...

Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with…

Thursday, June 4th, 2020

Company Announcement Copenhagen, Denmark; June 4, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for the subcutaneous (SC) formulation of DARZALEX (daratumumab), for the treatment of adult patients with multiple myeloma in all currently approved daratumumab intravenous (IV) formulation indications in frontline and relapsed / refractory settings. The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in April 2020. The SC formulation is administered as a fixed-dose over approximately three to five minutes, significantly less time than IV daratumumab, which is given over several hours

Read More...

Professor Wolf Reik appointed acting director of the Babraham Institute – Cambridge Independent

Thursday, June 4th, 2020

Professor Wolf Reik has been appointed acting director of the Babraham Institute. It follows the death of Professor Michael Wakelam, who died from suspected a Covid-19 infection on March 31

Read More...

Some types of prostate cancer may not be as aggressive as originally thought – Mirage News

Thursday, June 4th, 2020

UCLA Dr. Amar Kishan FINDINGS Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

Read More...

KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular…

Thursday, May 28th, 2020

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--May 28, 2020-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials evaluating KEYTRUDA, Mercks anti-PD-1 therapy, plus LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. In the KEYNOTE-524/Study 116 and KEYNOTE-146/Study 111 trials, the KEYTRUDA plus LENVIMA combination demonstrated clinically meaningful objective response rates (ORR) in patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and in patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively.

Read More...

Potential cross-reactivity between MMR vaccinations and COVID-19 | TheHill – The Hill

Wednesday, May 27th, 2020

With the current COVID-19 pandemic affecting the world, not much in everyday life remains the same. Economies from the largest to the smallest have been rocked

Read More...

What is a cytokine storm? And why is its prevention key to treating Covid-19? – Scroll.in

Wednesday, May 27th, 2020

The killer is not the virus but the immune response. The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable.

Read More...

Stem Cells Are Found to Protect Wounded Planarian by …

Saturday, May 23rd, 2020

Stem cells have always been known for their unlimited potential. Nowadays, the excellent qualities of them have expanded. A new study published in the journal Current Biology shows that these kinds of cells can delay their own deaths in response to physical injuries.

Read More...

Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 – TheStreet

Saturday, May 23rd, 2020

Courtesy of Alexander (Sasha) Poltorak, Tufts University The killer is not the virus but the immune response.

Read More...

Stem Cell or Bone Marrow Transplant Side Effects

Saturday, May 23rd, 2020

Problems soon after transplant Many of the problems that can happen shortly after the transplant come from having the bone marrow wiped out by medicines or radiation just before the transplant. Others may be side effects of the conditioning treatments themselves. Your transplant team can help you cope with side effects.

Read More...

Steady Improvements in the Survival of Norwegian Patients With Multiple Myeloma – Hematology Advisor

Saturday, May 23rd, 2020

Patientswith multiple myeloma (MM) had significant improvements in 5-year relativesurvival across all age groups since 1982, according to study results publishedin the British Journal of Haematology.The investigators noted that some improvements aligned with the historicalintroduction of treatment standards. Ateam of investigators leveraged data from the Cancer Registry of Norway, whichhas required compulsory reporting of all cancer cases by the countrys hospitals,laboratories, and general practitioners since 1953

Read More...

The Innovative Medicines Accelerator turns its focus on COVID-19 | Stanford News – Stanford University News

Saturday, May 23rd, 2020

As the worldwide COVID-19 pandemic continues to deliver both health and economic blows, hopes are pinned on medical researchers identifying drugs and vaccines needed to stop the viruss spread, heal those who are sick and ease concerns about returning to a semblance of normal. But the process of developing new medicines is a long one, and at best new vaccines can take more than a year

Read More...

Baby with liver disease receives Japan’s 1st ES cell transplant : The Asahi Shimbun – Asahi Shimbun

Saturday, May 23rd, 2020

A hospital in Tokyo said it successfully transplanted liver cells derived from human embryonic stem (ES) cells to a baby with a potentially life-threatening disease, marking the first time ES cells have been used to treat human diseases in Japan. The National Center for Child Health and Development (NCCHD) announced on May 21 thatitcarried out a clinical trial to transplant the cells into a baby with a severe liver disease.

Read More...

Page 11234..1020..»


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick